Mesoblast Limited (ASX: MSB | Nasdaq: MESO) has taken a critical step toward commercialising its lead cardiac product candidate, Revascor® (rexlemestrocel-L), with formal alignment reached with the United States Food and Drug Administration (FDA) on the key requirements for filing a Biologics License Application (BLA) in the treatment of ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation.

Mesoblast Limited (ASX:MSB; Nasdaq:MESO), the recognised global developer of allogeneic cellular medicines, has released an important update that reflects both regulatory momentum and commercial progress across its core programs in inflammatory diseases.